Toward Optimized ⁸⁹Zr-Immuno-PET: Side-by-Side Comparison of [⁸⁹Zr]Zr-DFO-, [⁸⁹Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [⁸⁹Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?

ABSTRACT: 89Zr represents a highly favorable positron emitter for application in immuno-PET (Positron Emission Tomography) imaging. Clinically, the 89Zr4+ ion is introduced into antibodies by complexation with desferrioxamine B. However, producing complexes of limited kinetic inertness. Therefore, several new chelators for 89Zr introduction have been developed over the last years. Of these, the direct comparison of the most relevant ones for clinical translation, DFO* and 3,4,3-(LI-1,2-HOPO), is still missing. Thus, we directly compared DFO with DFO* and 3,4,3-(LI-1,2-HOPO) immunoconjugates to identify the most suitable agent stable 89Zr-complexation. The chelators were introduced into cetuximab, and an optical analysis method was developed, enabling the efficient quantification of derivatization si

SUBMITTER: Damerow H 

PROVIDER: S-EPMC9611803 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature